| NEAL, MATTHEW D |
| Completed | 4 | 3591 | Europe, US, RoW | theraputic heparin, unfractionated heparin, Enoxaparin, Dalteparin, Tinzaparin, Heparin, prophylactic heparin, enoxaparin, dalteparin, Fondparinux, P2Y12, Ticagrelor, Prasugrel, Clopidogrel, Crizanlizumab Injection, SGLT2 inhibitor, dapagliflozin, empagliflozin, canagliflozin, ertugliflozin | Matthew Neal MD, National Heart, Lung, and Blood Institute (NHLBI) | Covid19 | 08/23 | 01/24 | | |
NCT04606264: Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data |
|
|
| Recruiting | 3 | 2500 | US | Neuraxial Analgesia, Intrathecal morphine/hydromorphone, IT morphine/hydromorphine, Regional Block 1: Paravertebral, Nerve Block, Perphenazine, Aprepitant, Dimenhydrinate, Ondansetron 4 MG, Dexamethasone, Regional Block 2: QL1 | Jennifer Holder-Murray, Berry Consultants | Perioperative Optimization | 06/25 | 06/25 | | |
| Recruiting | 3 | 328 | Europe, Canada, US | TAK-330, SOC 4F-PCC | Takeda, Takeda Development Center Americas, Inc. | Coagulation Disorder | 04/28 | 04/28 | | |
NCT06164691: Blue and Amber Light Exposure in Patients With Rectal and Pancreatic Cancer |
|
|
| Terminated | N/A | 2 | US | Blue light, Amber light, Ambient White Light | Matthew Neal MD | Pancreatic Neoplasms, Rectal Neoplasms | 04/23 | 04/23 | | |
| Recruiting | N/A | 75 | US | Bright Blue Light, Carex Day-Light Classic Plus Light Therapy Lamp, CCFDL93011, LEE Filters, Bright Full-Spectrum (White) Light, Usual Ambient Light | Rebecca E Kotcher, MD, National Institutes of Health (NIH), National Institute of General Medical Sciences (NIGMS) | Rib Fractures, Pain, Acute | 04/26 | 05/26 | | |
| Krans, Elizabeth E |
TOME, NCT06262347: Personally-Tailored Opioid-overdose and Medication for Opioid Use Disorder (MOUD) Education () for Pregnant and Postpartum Persons in MOUD |
|
|
| Completed | N/A | 131 | US | Personally-Tailored Opioid-overdose and Medication for opioid use disorder (MOUD) Education (TOME), Control | T. John Winhusen, PhD, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA) | Opioid Use Disorder, Pregnancy Related, Substance Use, Drug Abuse, Drug Abuse in Pregnancy, Drug Addiction | 11/24 | 11/24 | | |
STEPuP, NCT04527926: Prenatal Provider Education and Training to Improve Medication-assisted Treatment Use During Pregnancy |
|
|
| Enrolling by invitation | N/A | 1000 | US | STEPuP Intervention, Project STEPuP(Substance abuse Treatment and Education during Pregnancy and Postpartum), Usual Care | University of Pittsburgh, National Institute on Drug Abuse (NIDA) | Opioid-use Disorder, Pregnancy Related | 04/26 | 04/26 | | |
IMPACT, NCT04939012: Implementation of a Patient-centered, Reproductive Planning Decision Support Tool (MyPath) Among Women with Substance Use Disorder in the Immediate Postpartum Period |
|
|
| Recruiting | N/A | 400 | US | MyPath Intervention, Usual care | University of Pittsburgh, National Institute on Drug Abuse (NIDA) | Substance Use Disorders, Pregnancy Related, Contraception | 03/26 | 03/27 | | |
NCT05942313: Predicting and Preventing Adverse Maternal and Child Outcomes of Opioid Use Disorder in Pregnancy |
|
|
| Recruiting | N/A | 100 | US | Buprenorphine/ Methadone exposure, Opioid Use Disorder | Ilana Hull, National Institute on Drug Abuse (NIDA), OpalGenix, Inc | Opioid Use Disorder, Pregnancy Related | 12/25 | 12/25 | | |
| Waters, Jonathan |
NCT03633604: Expanded Access IND Administration of HBOC-201 in Patients With Severe Acute Anemia |
|
|
| Available | N/A | | US | HBOC-201, Hemopure, hemoglobin glutamer - 250 (bovine) | Jonathan H. Waters, HbO2 Therapeutics LLC | Anemia Severe | | | | |
| Burdin, Suzanne |
NCT05206331: CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study |
|
|
| Recruiting | 4 | 1855 | US | contrast enhanced mammography, Iodinated Contrast Media (ICM) | Margarita Louise Zuley, National Cancer Institute (NCI) | Breast Cancer | 11/26 | 11/27 | | |
NCT04484220: Ellipsys Vascular Access System Post Market Surveillance (PS) Study |
|
|
| Active, not recruiting | N/A | 142 | US | Ellipsys Vascular Access System | Medtronic Endovascular | Renal Disease, End Stage, Kidney Disease, End-Stage, AV Fistula, Fistulas Arteriovenous | 05/25 | 09/25 | | |
| Plassmeyer, Joshua |
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer |
|
|
| Recruiting | 3 | 418 | Europe, Canada, US, RoW | Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab | AbbVie, GOG Foundation | Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 03/27 | 04/29 | | |
| Active, not recruiting | 2 | 114 | US | Olaparib, AZD2281, KU-0059436 | Beth Israel Deaconess Medical Center, Johns Hopkins University, AstraZeneca, Dana-Farber Cancer Institute | Metastatic Breast Cancer, Invasive Breast Cancer, Somatic Mutation Breast Cancer (BRCA1), Somatic Mutation Breast Cancer (BRCA2), CHEK2 Gene Mutation, ATM Gene Mutation, PALB2 Gene Mutation, RAD51 Gene Mutation, BRIP1 Gene Mutation, NBN Gene Mutation | 07/25 | 12/25 | | |
| Active, not recruiting | 2 | 174 | US | Paclitaxel, Taxol, Onxal, Pertuzumab, Perjeta, Margetuximab, Margenza, Trastuzumab, Herceptin, Kanjinti, Ogivri, Herzuma | Dana-Farber Cancer Institute, MacroGenics, Translational Breast Cancer Research Consortium | Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer | 09/24 | 07/27 | | |
NCT05538091: Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer |
|
|
| Recruiting | 2 | 48 | US | Vismodegib, ERIVEDGE, Atezolizumab, Tecentriq | Ronald Buckanovich, Genentech, Inc. | Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, PARP Inhibitor, Hedgehog Inhibitor | 04/28 | 04/28 | | |
NCT05419817: Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System |
|
|
| Withdrawn | 2 | 30 | NA | pembrolizumab, Keytruda®, Sitravatinib | Haider Mahdi, Mirati Therapeutics Inc. | Recurrent Endometrial Cancer, Solid Tumors | 07/25 | 12/26 | | |
NCT05467670: Safety and Efficacy of Anti-CD47, ALX148 in Combination with Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer |
|
|
| Recruiting | 2 | 31 | US | Pembrolizumab, Keytruda®, ALX148, evorpacept, Doxorubicin, (Pegylated Liposomal Doxorubicin (PLD) | Alexander B Olawaiye, MD, ALX Oncology, Merck Sharp & Dohme LLC | Ovarian Cancer | 09/29 | 12/31 | | |
NCT06120972: Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency |
|
|
| Recruiting | 2 | 80 | US | Olaparib tablet, Lynparza | Alexander B Olawaiye, MD, AstraZeneca | Ovarian Cancer | 12/27 | 12/29 | | |
HCC 21-166, NCT05200559: T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 70 | US | Pembrolizumab, Keytruda®, E7777, ONTAK® | Alexander B Olawaiye, MD, Dr. Reddys Laboratories, SA | Epithelial Ovarian Cancer | 12/25 | 12/27 | | |
NCT05538624: A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary |
|
|
| Terminated | 1/2 | 14 | US | AVB-001 (Dose Escalation Phase), AVB-001 (Dose Expansion Phase) | Avenge Bio, Inc | Neoplasm, Ovarian, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenocarcinoma Ovary, Serous Adenocarcinoma of Ovary, Serous Adenocarcinoma of Primary Peritoneum, Primary Peritoneal Carcinoma, High Grade Serous Adenocarcinoma | 04/24 | 04/24 | | |
NCT06161493: ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors |
|
|
| Withdrawn | 1 | 26 | US | ZEN003694, Niraparib, MK-4827, Zejula | Haider Mahdi, GlaxoSmithKline, Zenith Epigenetics | Ovarian Cancer, Recurrent Solid Tumors | 12/26 | 12/29 | | |
NCT05942300: CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer |
|
|
| Recruiting | 1 | 30 | US | CPI-0209, Tulmimetostat, carboplatin | Lan Coffman, MorphoSys AG, National Cancer Institute (NCI) | Recurrent Ovarian Cancer | 01/27 | 08/29 | | |
| Recruiting | N/A | 30 | US | Doula - Patient engagement | University of Pittsburgh | Metastatic Cancer | 06/26 | 06/26 | | |
| Zuley, Margarita L |
NCT05206331: CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study |
|
|
| Recruiting | 4 | 1855 | US | contrast enhanced mammography, Iodinated Contrast Media (ICM) | Margarita Louise Zuley, National Cancer Institute (NCI) | Breast Cancer | 11/26 | 11/27 | | |
| Balish, Kelsey |
NCT04606264: Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data |
|
|
| Recruiting | 3 | 2500 | US | Neuraxial Analgesia, Intrathecal morphine/hydromorphone, IT morphine/hydromorphine, Regional Block 1: Paravertebral, Nerve Block, Perphenazine, Aprepitant, Dimenhydrinate, Ondansetron 4 MG, Dexamethasone, Regional Block 2: QL1 | Jennifer Holder-Murray, Berry Consultants | Perioperative Optimization | 06/25 | 06/25 | | |
| Zharichenko, Nicole |
NCT04606264: Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data |
|
|
| Recruiting | 3 | 2500 | US | Neuraxial Analgesia, Intrathecal morphine/hydromorphone, IT morphine/hydromorphine, Regional Block 1: Paravertebral, Nerve Block, Perphenazine, Aprepitant, Dimenhydrinate, Ondansetron 4 MG, Dexamethasone, Regional Block 2: QL1 | Jennifer Holder-Murray, Berry Consultants | Perioperative Optimization | 06/25 | 06/25 | | |
| Hull, Ilana |
NCT05942313: Predicting and Preventing Adverse Maternal and Child Outcomes of Opioid Use Disorder in Pregnancy |
|
|
| Recruiting | N/A | 100 | US | Buprenorphine/ Methadone exposure, Opioid Use Disorder | Ilana Hull, National Institute on Drug Abuse (NIDA), OpalGenix, Inc | Opioid Use Disorder, Pregnancy Related | 12/25 | 12/25 | | |
